On Friday, Compass Therapeutics Inc (NASDAQ: CMPX) opened lower -4.76% from the last session, before settling in for the closing price of $3.15. Price fluctuations for CMPX have ranged from $0.87 to $4.08 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -104.70%. Company’s average yearly earnings per share was noted -39.17% at the time writing. With a float of $87.95 million, this company’s outstanding shares have now reached $138.28 million.
Let’s determine the extent of company efficiency that accounts for 35 employees. In terms of profitability, gross margin is 100.0%, operating margin of -7273.41%, and the pretax margin is -6496.82%.
Compass Therapeutics Inc (CMPX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Compass Therapeutics Inc is 36.40%, while institutional ownership is 43.15%. The most recent insider transaction that took place on May 27 ’25, was worth 21,100. In this transaction CHIEF EXECUTIVE OFFICER of this company bought 10,000 shares at a rate of $2.11, taking the stock ownership to the 6,480,825 shares. Before that another transaction happened on Apr 09 ’25, when Company’s Director sold 3,571,428 for $1.59, making the entire transaction worth $5,678,571. This insider now owns 0 shares in total.
Compass Therapeutics Inc (CMPX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -39.17% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.37% during the next five years compared to -104.70% drop over the previous five years of trading.
Compass Therapeutics Inc (NASDAQ: CMPX) Trading Performance Indicators
Check out the current performance indicators for Compass Therapeutics Inc (CMPX). In the past quarter, the stock posted a quick ratio of 8.33. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 488.06.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.40, a number that is poised to hit -0.12 in the next quarter and is forecasted to reach -0.56 in one year’s time.
Technical Analysis of Compass Therapeutics Inc (CMPX)
Looking closely at Compass Therapeutics Inc (NASDAQ: CMPX), its last 5-days average volume was 0.93 million, which is a drop from its year-to-date volume of 1.44 million. As of the previous 9 days, the stock’s Stochastic %D was 77.10%.
During the past 100 days, Compass Therapeutics Inc’s (CMPX) raw stochastic average was set at 86.08%, which indicates a significant increase from 64.94% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.20 in the past 14 days, which was higher than the 0.19 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.39, while its 200-day Moving Average is $2.16. However, in the short run, Compass Therapeutics Inc’s stock first resistance to watch stands at $3.16. Second resistance stands at $3.31. The third major resistance level sits at $3.41. If the price goes on to break the first support level at $2.91, it is likely to go to the next support level at $2.81. Now, if the price goes above the second support level, the third support stands at $2.66.
Compass Therapeutics Inc (NASDAQ: CMPX) Key Stats
There are currently 138,283K shares outstanding in the company with a market cap of 414.85 million. Presently, the company’s annual sales total 850 K according to its annual income of -49,380 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -16,630 K.
